Johnson & Johnson In-process research and development decreased by 100.0% to $0.00 in Q2 2025 compared to the prior quarter. Year-over-year, this metric declined by 100.0%, from $194.00M to $0.00.
High charges indicate aggressive inorganic growth and pipeline acquisition, which may lead to future product launches.
In-process research and development charges represent the value assigned to R&D projects acquired through business combi...
Common in M&A-heavy sectors; comparable to acquired IPR&D charges at peer pharmaceutical companies.
is_jnj_in_process_research_and_development| Q2 '21 | Q3 '21 | Q4 '21 | Q2 '22 | Q4 '22 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q2 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $900.00M | $610.00M | $0.00 | $49.00M | $206.00M | $0.00 | $194.00M | $0.00 | $17.00M | $0.00 |
| QoQ Change | — | — | — | -32.2% | -100.0% | — | +320.4% | -100.0% | — | -100.0% | — | -100.0% |
| YoY Change | — | — | — | — | -100.0% | -92.0% | — | — | +295.9% | -100.0% | — | -100.0% |
We use cookies for analytics. See our Privacy and Cookie Policy.